Home › Funds › D. E. Shaw & Co › IBRX
D. E. Shaw & Co position in IBRX
IMMUNITYBIO INC · Health Care
Latest position (Q2 2026)11.55M sh
Reported value held$101.13M
Portfolio Weight0.05%
First reportedQ3 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 377.47K | $3.68M | New |
| Q4 2021 | 330.50K | $2.01M | Reduce |
| Q1 2022 | 95.27K | $534.00K | Reduce |
| Q2 2022 | 410.68K | $1.53M | Add |
| Q3 2022 | 678.50K | $3.37M | Add |
| Q4 2023 | 591.10K | $2.97M | New |
| Q1 2024 | 236.63K | $1.27M | Reduce |
| Q3 2024 | 520.05K | $1.93M | New |
| Q2 2025 | 237.15K | $626.07K | New |
| Q1 2026 | 12.57M | $96.42M | New |
| Q2 2026 | 11.55M | $101.13M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding IBRX
- BlackRock Inc 34.08M sh · $298.40M · Q2 2026
- Two Sigma Investments 11.10M sh · $97.16M · Q2 2026
- Geode Capital Management 9.85M sh · $86.23M · Q2 2026
- Vanguard Group 32.78M sh · $64.90M · Q4 2025
- Millennium Management 5.58M sh · $48.85M · Q2 2026
- Northern Trust Corp 3.57M sh · $31.21M · Q2 2026
- Morgan Stanley 3.43M sh · $30.05M · Q2 2026
- Goldman Sachs Group 3.23M sh · $28.32M · Q2 2026
- UBS Group AG 3.20M sh · $27.98M · Q2 2026
- Charles Schwab Investment Management 2.89M sh · $25.29M · Q2 2026
- Bank of America Corp 2.18M sh · $19.13M · Q2 2026